Drug Search Results
More Filters [+]

Luveltamab tazevibulin

Alternative Names: Luveltamab tazevibulin, stro-002, stro002, stro 002
Latest Update: 2025-01-07
Latest Update Note: News Article

Product Description

STRO-002, a folate receptor alpha (FolR_)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. (Sourced from: https://www.sutrobio.com/sutro-biopharma-announces-interim-data-from-dose-expansion-cohort-of-stro-002-phase-1-study-for-patients-with-advanced-ovarian-cancer/)

Mechanisms of Action: FR1 Antagonist

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: Fast Track - Ovarian Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sutro Biopharma, Inc.
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Luveltamab tazevibulin

Countries in Clinic: Australia, Austria, Belgium, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Korea, Netherlands, New Zealand, Singapore, Spain, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer

Phase 2: Acute Myeloid Leukemia|Non-Small-Cell Lung Cancer

Phase 1: Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

REFRaME-P1

P2

Unknown Status

Acute Myeloid Leukemia

2029-09-01

GLIS2 AML

P2

Recruiting

Acute Myeloid Leukemia

2028-12-01

REFRaME-O1

P3

Recruiting

Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer

2027-08-01

STRO-002-GM3

P2

Unknown Status

Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer

2027-05-31

Recent News Events